Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pulmonary Hypertension
Biotech
Keros ends hypertension trial over fluid buildups around heart
A month after halting dosing in two cohorts of a phase 2 trial of its pulmonary arterial hypertension drug, Keros has pulled the plug.
James Waldron
Jan 15, 2025 8:25am
Roivant unveils new ‘vant’ to advance Bayer hypertension med
Sep 10, 2024 7:57am
Gossamer touts phase 2 win but investors are wary
Dec 6, 2022 11:09am
ECG-enhancing AI scores FDA breakthrough nod
May 27, 2022 11:27am
